Literature DB >> 6563847

Rifampin in the treatment of serious staphylococcal infections.

L Swanberg, C U Tuazon.   

Abstract

Eight patients with serious staphylococcal infections such as endocarditis, meningitis, epidural abscess, shunt and graft infections were treated with nafcillin, cephalothin or vancomycin in combination with rifampin. In vitro antibiotic sensitivities demonstrated that the Staphylococcus aureus and Staphylococcus epidermidis were highly sensitive to rifampin with minimum inhibitory and bactericidal levels of .0078-.25 micrograms/ml. In all patients reviewed and reported, when serum bactericidal levels were measured before and after the addition of rifampin, there was a positive correlation between microbiological and clinical outcome. Thus, in selected patients with life-threatening infections caused by S. aureus and S. epidermidis rifampin should be considered an adjunctive therapy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6563847     DOI: 10.1097/00000441-198405000-00018

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  5 in total

1.  Efficacies of ofloxacin, rifampin, and clindamycin in treatment of Staphylococcus aureus abscesses and correlation with results of an in vitro assay of intracellular bacterial killing.

Authors:  D M Bamberger; B L Herndon; M Dew; R P Chern; H Mitchell; L E Summers; R F Marcus; S C Kim; P R Suvarna
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

2.  Efficacy of ticarcillin-clavulanic acid for treatment of experimental Staphylococcus aureus endocarditis in rats.

Authors:  E J Catherall; V Gillon; S Hurn; R Irwin; L Mizen
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

Review 3.  Rifampin as adjuvant treatment of Gram-positive bacterial infections: a systematic review of comparative clinical trials.

Authors:  I A Bliziotis; F Ntziora; K R Lawrence; M E Falagas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-12       Impact factor: 3.267

Review 4.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

5.  In vivo interactions of continuous flucloxacillin infusion and high-dose oral rifampicin in the serum of 15 patients with bone and soft tissue infections due to Staphylococcus aureus - a methodological and pilot study.

Authors:  Christian Garzoni; Ilker Uçkay; Wilson Belaieff; Dominique Breilh; Domizio Suvà; Elzbieta Huggler; Daniel Lew; Pierre Hoffmeyer; Louis Bernard
Journal:  Springerplus       Date:  2014-06-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.